• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

早期类风湿关节炎中健康评估问卷残疾进展:两个起始队列的系统评价与分析

Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.

作者信息

Norton Sam, Fu Bo, Scott David L, Deighton Chris, Symmons Deborah P M, Wailoo Allan J, Tosh Jonathan, Lunt Mark, Davies Rebecca, Young Adam, Verstappen Suzanne M M

机构信息

Psychology Department, Institute of Psychiatry, King׳s College London, London, UK.

Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, UK.

出版信息

Semin Arthritis Rheum. 2014 Oct;44(2):131-44. doi: 10.1016/j.semarthrit.2014.05.003. Epub 2014 May 9.

DOI:10.1016/j.semarthrit.2014.05.003
PMID:24925692
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4282305/
Abstract

OBJECTIVE

The Health Assessment Questionnaire is widely used for patients with inflammatory polyarthritis (IP) and its subset, rheumatoid arthritis (RA). In this study, we evaluated the progression of HAQ scores in RA (i) by systematically reviewing the published literature on the methods used to assess changes in functional disability over time and (ii) to study in detail HAQ progression in two large prospective observational studies from the UK.

METHODS

Data from two large inception cohorts, ERAS and NOAR, were studied to determine trajectories of HAQ progression over time by applying latent class growth models (LCGMs) to each dataset separately. Age, sex, baseline DAS28, symptom duration, rheumatoid factor, fulfilment of the 1987 ACR criteria and socio-economic status (SES) were included as potential predictors of HAQ trajectory subgroup membership.

RESULTS

The literature search identified 49 studies showing that HAQ progression has mainly been based on average changes in the total study population. In the HAQ progression study, a LCGM with four HAQ trajectory subgroups was selected as providing the best fit in both cohorts. In both the cohorts, older age, female sex, longer symptom duration, fulfilment of the 1987 ACR criteria, higher DAS28 and lower SES were associated with increased likelihood of membership of subgroups with worse HAQ progression.

CONCLUSION

Four distinct HAQ trajectory subgroups were derived from the ERAS and NOAR cohorts. The fact that the subgroups identified were nearly identical supports their validity. Identifying distinct groups of patients who are at risk of poor functional outcome may help to target therapy to those who are most likely to benefit.

摘要

目的

健康评估问卷广泛应用于炎症性多关节炎(IP)患者及其子集类风湿关节炎(RA)患者。在本研究中,我们通过系统回顾已发表的关于评估功能残疾随时间变化方法的文献,以及在英国两项大型前瞻性观察性研究中详细研究RA患者的健康评估问卷(HAQ)进展情况,来评估RA患者HAQ评分的进展。

方法

研究了两个大型起始队列ERAS和NOAR的数据,通过分别对每个数据集应用潜在类别增长模型(LCGM)来确定HAQ随时间的进展轨迹。年龄、性别、基线疾病活动评分28(DAS28)、症状持续时间、类风湿因子、是否符合1987年美国风湿病学会(ACR)标准以及社会经济地位(SES)被纳入作为HAQ轨迹亚组归属的潜在预测因素。

结果

文献检索确定了49项研究,表明HAQ进展主要基于整个研究人群的平均变化。在HAQ进展研究中,选择了一个具有四个HAQ轨迹亚组的LCGM,因为它在两个队列中拟合效果最佳。在两个队列中,年龄较大、女性、症状持续时间较长、符合1987年ACR标准、较高的DAS28以及较低的SES与HAQ进展较差的亚组归属可能性增加相关。

结论

从ERAS和NOAR队列中得出了四个不同的HAQ轨迹亚组。所确定的亚组几乎相同这一事实支持了它们的有效性。识别出功能结局较差风险较高的不同患者群体可能有助于将治疗靶向最可能受益的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/57f2645399d0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/7d6a3ea91676/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/41c59e67bfcd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/57f2645399d0/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/7d6a3ea91676/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/41c59e67bfcd/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e076/4282305/57f2645399d0/gr3.jpg

相似文献

1
Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.早期类风湿关节炎中健康评估问卷残疾进展:两个起始队列的系统评价与分析
Semin Arthritis Rheum. 2014 Oct;44(2):131-44. doi: 10.1016/j.semarthrit.2014.05.003. Epub 2014 May 9.
2
Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、聚乙二醇化赛妥珠单抗、戈利木单抗、托珠单抗和阿巴西普用于治疗既往未使用改善病情抗风湿药物治疗且仅在传统改善病情抗风湿药物治疗失败后的类风湿关节炎:系统评价和经济学评估。
Health Technol Assess. 2016 Apr;20(35):1-610. doi: 10.3310/hta20350.
3
A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.阿达木单抗、依那西普和英夫利昔单抗治疗成人类风湿关节炎有效性的系统评价及其成本效益的经济学评估。
Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.
4
Biologics or tofacitinib for people with rheumatoid arthritis unsuccessfully treated with biologics: a systematic review and network meta-analysis.生物制剂或托法替布用于生物制剂治疗类风湿关节炎失败的患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 Mar 10;3(3):CD012591. doi: 10.1002/14651858.CD012591.
5
Biologics or tofacitinib for people with rheumatoid arthritis naive to methotrexate: a systematic review and network meta-analysis.生物制剂或托法替布用于初治类风湿关节炎患者:一项系统评价和网状Meta分析
Cochrane Database Syst Rev. 2017 May 8;5(5):CD012657. doi: 10.1002/14651858.CD012657.
6
Biologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA).生物制剂或托法替布单药治疗传统抗风湿药物(DMARD)治疗失败的类风湿关节炎患者:一项Cochrane系统评价和网状Meta分析(NMA)
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD012437. doi: 10.1002/14651858.CD012437.
7
Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.依那西普和英夫利昔单抗治疗银屑病关节炎:系统评价与经济学评估
Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. doi: 10.3310/hta10310.
8
Rituximab for rheumatoid arthritis.利妥昔单抗用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2015 Jan 20;1(1):CD007356. doi: 10.1002/14651858.CD007356.pub2.
9
Methotrexate for treating rheumatoid arthritis.甲氨蝶呤用于治疗类风湿关节炎。
Cochrane Database Syst Rev. 2014 Jun 10;2014(6):CD000957. doi: 10.1002/14651858.CD000957.pub2.
10
Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.阿达木单抗、依那西普、英夫利昔单抗、利妥昔单抗和阿巴西普治疗肿瘤坏死因子抑制剂治疗失败后的类风湿关节炎:系统评价和经济评估。
Health Technol Assess. 2011 Mar;15(14):1-278. doi: 10.3310/hta15140.

引用本文的文献

1
Comparing nurse-led and rheumatologist-led care for rheumatoid arthritis patients: a systematic review and meta-analysis of randomized controlled trials.比较护士主导和风湿病专家主导的类风湿性关节炎患者护理:随机对照试验的系统评价和荟萃分析
Rev Esc Enferm USP. 2025 Jun 20;59:e20240186. doi: 10.1590/1980-220X-REEUSP-2024-0186en. eCollection 2025.
2
Current and Future Challenges for Rehabilitation for Inflammatory Arthritis.炎症性关节炎康复的当前及未来挑战
J Clin Med. 2024 Mar 21;13(6):1808. doi: 10.3390/jcm13061808.
3
Patterns of comorbidities differentially affect long-term functional evolution and disease activity in patients with 'difficult to treat' rheumatoid arthritis.

本文引用的文献

1
Trajectories of functional limitation in early rheumatoid arthritis and their association with mortality.早期类风湿关节炎患者功能受限的轨迹及其与死亡率的关系。
Rheumatology (Oxford). 2013 Nov;52(11):2016-24. doi: 10.1093/rheumatology/ket253. Epub 2013 Aug 8.
2
Do patients with elderly-onset rheumatoid arthritis have severe functional disability?老年发病的类风湿关节炎患者是否存在严重的功能残疾?
Semin Arthritis Rheum. 2012 Aug;42(1):23-31. doi: 10.1016/j.semarthrit.2012.02.004. Epub 2012 Mar 31.
3
The relationship between joint damage and functional disability in rheumatoid arthritis: a systematic review.
共病模式对“难治性”类风湿关节炎患者的长期功能演变和疾病活动有不同影响。
RMD Open. 2024 Jan 19;10(1):e003808. doi: 10.1136/rmdopen-2023-003808.
4
Prevalence and Predictors of Remission and Sustained Remission in Patients with Rheumatoid Arthritis from the United Arab Emirates: A Two-Year Prospective Study.阿联酋类风湿关节炎患者缓解和持续缓解的患病率及预测因素:一项为期两年的前瞻性研究。
Open Access Rheumatol. 2023 May 10;15:51-63. doi: 10.2147/OARRR.S408894. eCollection 2023.
5
Influence of Social Support, Financial Status, and Lifestyle on the Disparity Between Inflammation and Disability in Rheumatoid Arthritis.社会支持、经济状况和生活方式对类风湿关节炎炎症与残疾差异的影响。
Arthritis Care Res (Hoboken). 2023 May;75(5):1026-1035. doi: 10.1002/acr.24996. Epub 2022 Dec 28.
6
Inflammatory profile of incident cases of late-onset compared with young-onset rheumatoid arthritis: A nested cohort study.迟发型与早发型类风湿关节炎新发病例的炎症特征:一项巢式队列研究。
Front Med (Lausanne). 2022 Nov 8;9:1016159. doi: 10.3389/fmed.2022.1016159. eCollection 2022.
7
Differences in trajectory of disease activity according to biologic and targeted synthetic disease-modifying anti-rheumatic drug treatment in patients with rheumatoid arthritis.类风湿关节炎患者接受生物制剂和靶向合成改善病情抗风湿药物治疗后疾病活动度轨迹的差异。
Arthritis Res Ther. 2022 Oct 14;24(1):233. doi: 10.1186/s13075-022-02918-3.
8
Disease activity trajectories for early and established rheumatoid arthritis: Real-world data from a rheumatoid arthritis cohort.早期和已确立的类风湿关节炎的疾病活动轨迹:类风湿关节炎队列的真实世界数据。
PLoS One. 2022 Sep 7;17(9):e0274264. doi: 10.1371/journal.pone.0274264. eCollection 2022.
9
Robust estimation of models for longitudinal data with dropouts and outliers.针对含缺失值和异常值的纵向数据模型的稳健估计。
J Appl Stat. 2020 Nov 10;49(4):902-925. doi: 10.1080/02664763.2020.1845623. eCollection 2022.
10
Characterization of disease course and remission in early seropositive rheumatoid arthritis: results from the TACERA longitudinal cohort study.早期血清阳性类风湿关节炎疾病进程与缓解的特征:TACERA纵向队列研究结果
Ther Adv Musculoskelet Dis. 2021 Oct 21;13:1759720X211043977. doi: 10.1177/1759720X211043977. eCollection 2021.
类风湿关节炎中关节损伤与功能障碍的关系:系统综述。
Ann Rheum Dis. 2012 Jun;71(6):836-44. doi: 10.1136/annrheumdis-2011-200343. Epub 2011 Nov 29.
4
Social support and psychological distress in rheumatoid arthritis: a 4-year prospective study.类风湿关节炎患者的社会支持与心理困扰:一项为期 4 年的前瞻性研究。
Disabil Rehabil. 2012;34(9):754-61. doi: 10.3109/09638288.2011.619618. Epub 2011 Oct 17.
5
Differences in activity limitation, pain intensity, and global health in patients with rheumatoid arthritis in Sweden and the USA: a 5-year follow-up.瑞典和美国类风湿关节炎患者活动受限、疼痛强度和总体健康状况的差异:5 年随访。
Scand J Rheumatol. 2011 Nov;40(6):428-32. doi: 10.3109/03009742.2011.594963. Epub 2011 Sep 21.
6
Anti-cyclic citrullinated peptide antibody predicts functional disability in patients with rheumatoid arthritis in a large prospective observational cohort in Japan.抗环瓜氨酸肽抗体可预测日本大型前瞻性观察队列中类风湿关节炎患者的功能残疾。
Rheumatol Int. 2012 Feb;32(2):361-6. doi: 10.1007/s00296-010-1671-3. Epub 2010 Nov 27.
7
Treatment and nontreatment predictors of health assessment questionnaire disability progression in rheumatoid arthritis: a longitudinal study of 18,485 patients.类风湿关节炎健康评估问卷残疾进展的治疗和非治疗预测因素:对 18485 例患者的纵向研究。
Arthritis Care Res (Hoboken). 2011 Mar;63(3):366-72. doi: 10.1002/acr.20405. Epub 2010 Nov 15.
8
Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis.合并症会影响类风湿关节炎患者身体功能和生活质量的所有领域。
Rheumatology (Oxford). 2011 Feb;50(2):381-8. doi: 10.1093/rheumatology/keq334. Epub 2010 Oct 29.
9
Health-related quality of life and continuation rate on first-line anti-tumour necrosis factor therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database.澳大利亚风湿病学会数据库中类风湿关节炎患者一线抗肿瘤坏死因子治疗的健康相关生活质量和持续率。
Rheumatology (Oxford). 2011 Jan;50(1):166-75. doi: 10.1093/rheumatology/keq322. Epub 2010 Oct 7.
10
The loss of health status in rheumatoid arthritis and the effect of biologic therapy: a longitudinal observational study.类风湿关节炎患者健康状况的丧失及生物治疗的影响:一项纵向观察性研究。
Arthritis Res Ther. 2010;12(2):R35. doi: 10.1186/ar2944. Epub 2010 Mar 2.